François Grand’Maison

Author

Also Known As

C. Ayotte, Cavit Boz, D Ferraro, Duquette P, Eva Kubala Havrdova, F Grand'Maison, F Grand’Maison, F. GRAND'MAISON, F. Grand'Maison, F. Grand’Maison

175

Publications

10.2K

Citations

H-Index

Concepts

All Affiliations

The Royal Melbourne Hospital The University of Melbourne University of Bari Aldo Moro Hospital Universitario Virgen Macarena Monash University

About

François Grand’Maison is an author at The Royal Melbourne Hospital specializing in medicine, multiple sclerosis, and neurology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	23	4.2K
2	Health Sciences	7	7	1.6K
3	Public Health	5	5	1K
4	Engineering	1	1	18
5	Nursing	1	1	40

François Grand’Maison

Publications

9.4K

Citations

H-Index

Page 1

	Year	Citations
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study Ludwig Kappos, Amit Bar‐Or, Bruce Cree, The Lancet Neurological DisorderClinical NeurologyClinical TrialsSiponimod Versus PlaceboNeurological Monitoring	2018	896
Peripheral Nerve Function in Sepsis and Multiple Organ Failure Norbert J. Witt, Douglas W. Zochodne, Charles F. Bolton, CHEST Journal InflammationPeripheral Nerve FunctionPeripheral Nerve InjurySepsisPeripheral Nerve	1991	578
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis J William L Brown, Alasdair Coles, Dana Horáková, JAMA	2019	511
Defining secondary progressive multiple sclerosis Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis, Brain Neurological DisorderDisabilityClinical NeurologyNeurological ProgressNeurological Rehabilitation	2016	401
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study Anna He, B. Merkel, J William L Brown, The Lancet Neurology Disease ProgressionNeurological DisorderClinical EpidemiologyClinical TrialsOutcomes Research	2020	401
Incidence of acquired demyelination of the CNS in Canadian children Brenda Banwell, J. Kennedy, Douglas L. Arnold, Neurology	2009	366
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension Raju Kapoor, Pei‐Ran Ho, Nolan Campbell, The Lancet Neurology Disease ProgressionNeurological DisorderImmunologyClinical TrialsNeurology	2018	327
Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study Brenda Banwell, Amit Bar‐Or, Douglas L. Arnold, The Lancet Neurology Neurological DisorderMedicineGenetic EpidemiologyPediatricsClinical Neurology	2011	314
Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis Olaf Stüve, Christina M. Marra, Amit Bar‐Or, Archives of Neurology	2006	270
MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis Helmut Butzkueven, Joab Chapman, Edgardo Cristiano, Multiple Sclerosis Journal Observational Cohort StudiesProspective Cohort StudyPatient-reported OutcomeNeurologyPublic Health	2006	235

Page 1